Treatments of peripheral artery disease: cost-effectiveness analyses
- Original publication: Burgers LT, Luyendijk M, Poley MJ, Severens JL, Redekop WK. Systematic review of cost-effectiveness analyses of treatments of peripheral artery disease. Report from Erasmus University Rotterdam, Institute of Health Policy & Management. The Netherlands, 2015.
- This KCE has read for you was prepared by Joan Vlayen, Nancy Thiry and Sabine Stordeur
- Published on 28 September 2017
KEY MESSAGES OF THE ORIGINAL PUBLICATION
For patients with intermittent claudication:
- Supervised exercise therapy is cost-effective compared with unsupervised exercise therapy.
- Compared with supervised exercise therapy, revascularization improves health but increases costs; whether the health gain justifies the additional costs is not clear from the studies.
- Percutaneous transluminal angioplasty with stent placement for iliac revascularizations is cost-effective compared with percutaneous transluminal angioplasty alone.
- Percutaneous transluminal angioplasty is cost-effective compared with bypass for femoropopliteal interventions.
For patients with critical limb ischemia:
- Revascularisation (bypass or percutaneous transluminal angioplasty) is a cost-effective treatment compared with primary amputation.
- It is however unclear whether bypass or endovascular treatment is costeffective.
KCE has read for you synthesises a recently published high-quality systematic review or health technology assessment with relevance for the Belgian health system.
The original publication was appraised and contextualised by KCE researchers. KCE has read for you is not based on original research conducted by KCE.
More details on methodology can be found on the KCE website.
This document includes
- Key findings of the publication under evaluation
- A contextualisation within the Belgian healthcare system
- Detailed descriptions
Trustworthy original publication
The methodological quality of the systematic review was assessed with the AMSTAR tool.